News

Conference Coverage

NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers

06/29/2023

According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.

According to phase 3 data...

06/29/2023

Oncology

Conference Coverage

Novel FGFR TKI Demonstrated Efficacy and Safety for Patients With Advanced Intrahepatic Cholangiocarcinoma

06/02/2023

Allison Casey ;

The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.

The FGFR-selective tyrosine...

06/02/2023

Oncology

Milind Javle, MD, MD Anderson Cancer Center

Videos

The Changing Treatment Landscape of Cholangiocarcinoma

04/12/2023

At the 2023 Great Debates and Updates in GI Malignancies, Milind Javle, MD, discusses the recent developments in the treatment of patients with cholangiocarcinoma.

At the 2023 Great Debates and...

04/12/2023

Oncology

Videos

Recent Approvals for Cholangiocarcinoma Treatment

04/06/2023

While at the 2023 Great Debates and Updates in GI Malignancies meeting in Chicago, Milind Javle, MD, reviews the latest FDA approvals in the cholangiocarcinoma space.

While at the 2023 Great Debates...

04/06/2023

Oncology

Alison Schram, MD, Memorial Sloan Kettering Cancer Center

Videos

Targeting Class II/III Alterations in BRAF Inhibitors

03/16/2023

At 2023 ESMO Targeted Anticancer Therapies Congress, Alison Schram, MD, discusses the class II/III alterations of BRAF inhibitors.

At 2023 ESMO Targeted Anticancer...

03/16/2023

Oncology

Firas Baidoun, MD, Mayo Clinic - Florida

Videos

Neoadjuvant Chemotherapy Demonstrates Survival Benefit for Patients With Stage III Cholangiocarcinoma

03/06/2023

Firas Baidoun, MD, discusses an abstract presented at 2023 ASCO Gastrointestinal Cancers Symposium evaluating peri-operative chemotherapy for patients with non-metastatic cholangiocarcinoma.

Firas Baidoun, MD, discusses an...

03/06/2023

Oncology

Rachna Shroff, MD, University of Arizona Cancer Center

Videos

No Survival Benefit From Addition of Nab-paclitaxel to Gemcitabine-Cisplatin for Patients With Biliary Tract Cancers

01/26/2023

Rachna Shroff, MD, shares data from a phase 3 trial evaluating gemcitabine, cisplatin, and nab-paclitaxel for newly diagnosed, advanced biliary tract cancers.

Rachna Shroff, MD, shares data...

01/26/2023

Oncology

Conference Coverage

Nanvuranlat Demonstrated Clinical Activity for Advanced, Refractory Biliary Tract Cancers

01/20/2023

Allison Casey ;

According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...

According to a phase 2 trial...

01/20/2023

Oncology

News

Annual MRI for Patients With Primary Sclerosing Cholangitis Failed to Provide Long-Term Cholangiocarcinoma Survival Benefit

11/21/2022

Allison Casey ;

Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.

Among patients with primary...

11/21/2022

Oncology

News

Trastuzumab Biosimilar Plus FOLFOX Shows Promise for HER2-Positive Biliary Tract Cancers

11/10/2022

In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.

In a phase 2 trial, trastuzumab...

11/10/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology